Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE: Bavituximab + Docetaxel in 2nd-line Non-Squamous NSCLC
NCT01999673Phase 3Completed
- Sponsor
- Avid Bioservices, Inc.
- Start
- Dec 2013
- Primary completion
- Mar 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of bavituximab in non-small cell lung cancer (NSCLC), sponsored by Avid Bioservices, Inc.. Started Dec 2013; status: completed.
02
Drugs
bavituximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01999673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999673.